Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
COM701 · 2 trials · 11 indications
Progression free survival in COM701-treated participants compared to placebo-treated participants
To evaluate the safety profile of COM701 monotherapy and in combination with nivolumab.
| Arm | Type | Description |
|---|---|---|
| COM701 | EXPERIMENTAL | - |
| Normal Saline | PLACEBO_COMPARATOR | - |
| P1a Arm A (Monotherapy Dose Escalation). | EXPERIMENTAL | COM701 monotherapy sequential dose escalation administered IV every 3 weeks and a Cohort IV every 4 weeks. Up to 8 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended phase 2 dose is identified. |
| P1a Arm B (Combination Dose Escalation). | EXPERIMENTAL | COM701 sequential dose escalation administered IV every 3 weeks in combination with Opdivo (Nivolumab) 360mg administered IV every 3 weeks and COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480mg administered IV every 4 weeks. |
| P1a Arm A (Monotherapy Expansion). | EXPERIMENTAL | COM701 monotherapy administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (NSCLC, Breast, Ovarian, Endometrial and Colorectal cancer). |
| P1b (Combination Cohort Dose Expansion). | EXPERIMENTAL | COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480 mg administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (Breast, Ovarian, Endometrial and Colorectal cancer). |
| Name | Type | Description |
|---|---|---|
| COM701 | DRUG | COM701 will be administered via intravenous (IV) infusion once every 3 weeks. |
| Normal Saline | DRUG | Saline will be administered via intravenous (IV) infusion once every 3 weeks |
| COM701 with Opdivo (Nivolumab). | DRUG | COM701 in combination with Opdivo (Nivolumab). |
Inclusion Criteria: * Has relapsed platinum sensitive epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer * Has completed at least 2 previous courses (i.e. lines) of platinum-containing therapy * For the last chemotherapy course prior to being randomized into the study, mu...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
COM701 is an investigational small molecule being developed for the treatment of advanced solid tumors, including ovarian cancer. It is being studied in patients with advanced cancer, ovarian cancer, breast cancer, lung cancer, endometrial cancer, and colorectal cancer. The drug is currently in Phase 1 clinical development and is not yet approved by the FDA.
COM701 targets PVRIG, a protein involved in immune regulation. By inhibiting PVRIG, COM701 is designed to modulate the immune system's response to cancer cells. This mechanism is being evaluated in clinical trials for its potential to treat advanced solid tumors, including ovarian cancer.
COM701 is being developed by Compugen Ltd., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CGEN. The company is conducting clinical trials to evaluate the safety and efficacy of COM701 in patients with advanced solid tumors and ovarian cancer.
COM701 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in early-stage trials to assess its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors and ovarian cancer.
COM701 is being evaluated in two Phase 1 clinical trials. The first, NCT03667716, is a completed study in patients with advanced solid tumors, enrolling 121 participants in the United States. The second, NCT06888921, is currently recruiting patients with relapsed platinum-sensitive ovarian cancer, with a target enrollment of 60 participants across the United States, France, and Israel.
COM701 is a unique investigational drug developed by Compugen Ltd. It is not known to be the same as any other approved or marketed medication. Its distinct mechanism of targeting PVRIG sets it apart from other cancer therapies currently in development.